Value £55,488,141

Maxion Therapeutics

VC Funding

Series A £50m+ Angel-backed

Healthcare & Biotech Published 17 March 2025

Summary

In a significant market movement during March 2025, Maxion Therapeutics was the subject of a vc funding. The transaction achieved a gross valuation of £55,488,141. Leading the round was Solasta Ventures, General Catalyst, LifeArc Ventures, BGF, Eli lilly and company, British Patient Capital, Monograph Capital.

This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.

Lead Investor / Acquirer

Solasta Ventures

Lead Investor / Acquirer

General Catalyst

Lead Investor / Acquirer

LifeArc Ventures

Lead Investor / Acquirer

BGF

Lead Investor / Acquirer

Eli lilly

Lead Investor / Acquirer

company

Lead Investor / Acquirer

British Patient Capital

Lead Investor / Acquirer

Monograph Capital

Advising Broker

Undisclosed Firm

Related Deals in Healthcare & Biotech

Series A prioritised

VC Funding

Newcells Biotech

£2,350,000

Feb 2024

VC Funding

HutanBio

£2,250,000

Jan 2024

VC Funding

Lottie

£17,253,062

Oct 2023

VC Funding

Skin Analytics

£4,000,000

Sept 2020

View Company Details

Financials, officers, full deal history

Original Source

This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.

View on Tech.eu Funding Explorer

Funding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.

AI Insight Lenses

Pro

AI-generated analysis from four professional perspectives. Powered by PE Deals.

Free to all registered users.